Protective effect of scFv-DAF fusion protein on the complement attack to acetylcholine receptor: A possible option for treatment of myasthenia gravis

Muscle and Nerve

Volumn 45, Issue 5, 2012, Pages 668-675

  Song, Chen ^a   Xu, Zhikai ^b   Miao, Jianting ^a   Xu, Jiang ^a   Wu, Xingan ^b   Zhang, Fanglin ^b   Lin, Hong ^a   Li, Zhuyi ^a   Kaminski, Henry J ^c  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Decay accelerating factor; Fusion protein; Myasthenia gravis; Single chain antibody fragment; Targeting

Indexed keywords

CHOLINERGIC RECEPTOR; COMPLEMENTARY DNA; HYBRID PROTEIN; MONOCLONAL ANTIBODY; NEUROPROTECTIVE AGENT; RECOMBINANT PROTEIN; SINGLE CHAIN ANTIBODY FRAGMENT DECAY ACCELERATING FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING KINETICS; COMPETITIVE INHIBITION; COMPLEMENT ACTIVATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; IN VITRO STUDY; MYASTHENIA GRAVIS; NEUROPROTECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROKARYOTE; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN TARGETING; RAT; RECOMBINANT PLASMID; SEQUENCE ANALYSIS; WESTERN BLOTTING; WILD TYPE;

ANIMALS; ANTIGENS, CD55; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; COMPLEMENT SYSTEM PROTEINS; CRICETINAE; CRICETULUS; FLOW CYTOMETRY; HUMANS; PROTEIN BINDING; RATS; RECEPTORS, CHOLINERGIC; RECOMBINANT FUSION PROTEINS; RHABDOMYOSARCOMA; SINGLE-CHAIN ANTIBODIES;

EID: 84859734581     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23247     Document Type: Article

References (43)

1. Drachman DB. Myasthenia gravis. N Engl J Med 1994; 330: 1797-1810.
2. Lindstrom JM. Acetylcholine receptors and myasthenia. Muscle Nerve 2000; 23: 453-477.
3. Vincent A, Lang B, Kleopa KA. Autoimmune channelopathies and related neurological disorders. Neuron 2006; 52: 123-138.
4. Lennon VA, Seybold ME, Lindstrom JM, Cochrane C, Ulevitch R. Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J Exp Med 1978; 147: 973-983.
5. Christadoss P. C5 gene influences the development of murine myasthenia gravis. J Immunol 1988; 140: 2589-2592.
6. Morgan BP, Chamberlain-Banoub J, Neal JW, Song W, Mizuno M, Harris CL. The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice. Clin Exp Immunol 2006; 146: 294-302.
7. Engel AG, Lambert EH, Howard FM. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc 1977; 52: 267-280.
8. Sahashi K, Engel AG, Lambert EH, Howard FM Jr. Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis. J Neuropathol Exp Neurol 1980; 39: 160-172.
9. Zhou Y, Gong B, Lin F, Rother RP, Medof ME, Kaminski HJ. Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis. J Immunol 2007; 179: 8562-8567.
10. Piddlesden SJ, Jiang S, Levin JL, Vincent A, Morgan BP. Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis. J Neuroimmunol 1996; 71: 173-177.
11. Miwa T, Song WC. Membrane complement regulatory proteins: insight from animal studies and relevance to human diseases. Int Immunopharmacol 2001; 1: 445-459.
12. Kaminski HJ, Kusner LL, Richmonds C, Medof ME, Lin F. Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia. Exp Neurol 2006; 202: 287-293.
13. Lin F, Kaminski HJ, Conti-Fine BM, Wang W, Richmonds C, Medof ME. Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. J Clin Invest 2002; 110: 1269-1274.
14. Moran P, Beasley H, Gorrell A, Martin E, Gribling P, Fuchs H, et al. Human recombinant soluble decay accelerating factor inhibits complement activation in vitro and in vivo. J Immunol 1992; 149: 1736-1743.
15. Linton SM, Williams AS, Dodd I, Smith R, Williams BD, Morgan BP. Therapeutic efficacy of a novel membrane-targeted complement regulator in antigen-induced arthritis in the rat. Arthritis Rheum 2000; 43: 2590-2597.
16. Song H, He C, Knaak C, Guthridge JM, Holers VM, Tomlinson S. Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation. J Clin Invest 2003; 111: 1875-1885.
17. Zhang HF, Yu J, Bajwa E, Morrison SL, Tomlinson S. Targeting of functional antibody-CD59 fusion proteins to a cell surface. J Clin Invest 1999; 103: 55-61.
18. Zhang H, Lu S, Morrison SL, Tomlinson S. Targeting of functional antibody-decay-accelerating factor fusion proteins to a cell surface. J Biol Chem 2001; 276: 27290-27295.
19. Spitzer D, Unsinger J, Bessler M, Atkinson JP. ScFv-mediated in vivo targeting of DAF to erythrocytes inhibits lysis by complement. Mol Immunol 2004; 40: 911-919.
20. Tzartos SJ, Sophianos D, Efthimiadis A. Role of the main immunogenic region of acetylcholine receptor in myasthenia gravis. An Fab monoclonal antibody protects against antigenic modulation by human sera. J Immunol 1985; 134: 2343-2349.
21. Mamalaki A, Trakas N, Tzartos SJ. Bacterial expression of a single-chain Fv fragment which efficiently protects the acetylcholine receptor against antigenic modulation caused by myasthenic antibodies. Eur J Immunol 1993; 23: 1839-1845.
22. Tzartos SJ, Barkas T, Cung MT, Mamalaki A, Marraud M, Orlewski P, et al. Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor. Immunol Rev 1998; 163: 89-120.
23. Tsantili P, Tzartos SJ, Mamalaki A. High affinity single-chain Fv antibody fragments protecting the human nicotinic acetylcholine receptor. J Neuroimmunol 1999; 94: 15-27.
24. Tzartos SJ, Changeux JP. High affinity binding of alpha-bungarotoxin to the purified alpha-subunit and to its 27, 000-dalton proteolytic peptide from Torpedo marmorata acetylcholine receptor. Requirement for sodium dodecyl sulfate. EMBO J 1983; 2: 381-387.
25. Miwa T, Okada N, Okada H. Alternative exon usage in the 3' region of a single gene generates glycosylphosphatidylinositol-anchored and transmembrane forms of rat decay-accelerating factor. Immunogenetics 2000; 51: 129-137.
26. Huston EE, Grammer JC, Yount RG. Flexibility of the myosin heavy chain: direct evidence that the region containing SH1 and SH2 can move 10 A under the influence of nucleotide binding. Biochemistry 1988; 27: 8945-8952.
27. Heckman KL, Pease LR. Gene splicing and mutagenesis by PCR-driven overlap extension. Nat Protoc 2007; 2: 924-932.
28. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
29. Xu J, Hu Y, Gong M, Sun C, Xu Z, Li Z, Wu X. An improved method for refolding recombinant decay accelerating factor for therapeutic studies. Protein Expr Purif 2009; 66: 102-106.
30. Tsouloufis T, Mamalaki A, Remoundos M, Tzartos SJ. Reconstitution of conformationally dependent epitopes on the N-terminal extracellular domain of the human muscle acetylcholine receptor alpha subunit expressed in Escherichia coli: implications for myasthenia gravis therapeutic approaches. Int Immunol 2000; 12: 1255-1265.
31. Harris CL, Williams AS, Linton SM, Morgan BP. Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo. Clin Exp Immunol 2002; 129: 198-207.
32. Lin F, Immormino RM, Shoham M, Medof ME. Bulk production and functional analyses of mouse CD55's native and deglycosylated active domains. Arch Biochem Biophys 2001; 393: 67-72.
33. Syapin PJ, Salvaterra PM, Engelhardt JK. Neuronal-like features of TE671 cells: presence of a functional nicotinic cholinergic receptor. Brain Res 1982; 231: 365-377.
34. Niehans GA, Cherwitz DL, Staley NA, Knapp DJ, Dalmasso AP. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am J Pathol 1996; 149: 129-142.
35. Bodian DL, Davis SJ, Morgan BP, Rushmere NK. Mutational analysis of the active site and antibody epitopes of the complement-inhibitory glycoprotein, CD59. J Exp Med 1997; 185: 507-516.
36. Harris CL, Spiller OB, Morgan BP. Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities. Immunology 2000; 100: 462-470.
37. Tzartos S, Hochschwender S, Vasquez P, Lindstrom J. Passive transfer of experimental autoimmune myasthenia gravis by monoclonal antibodies to the main immunogenic region of the acetylcholine receptor. J Neuroimmunol 1987; 15: 185-194.
38. Chamberlain-Banoub J, Neal JW, Mizuno M, Harris CL, Morgan BP. Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats. Clin Exp Immunol 2006; 146: 278-286.
39. Guyon T, Wakkach A, Poea S, Mouly V, Klingel-Schmitt I, Levasseur P, et al. Regulation of acetylcholine receptor gene expression in human myasthenia gravis muscles. Evidences for a compensatory mechanism triggered by receptor loss. J Clin Invest 1998; 102: 249-263.
40. Medof ME, Kinoshita T, Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med 1984; 160: 1558-1578.
41. Tzartos SJ, Seybold ME, Lindstrom JM. Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies. Proc Natl Acad Sci USA 1982; 79: 188-192.
42. Christiansen D, Milland J, Thorley BR, McKenzie IF, Mottram PL, Purcell LJ, et al. Engineering of recombinant soluble CD46: an inhibitor of complement activation. Immunology 1996; 87: 348-354.
43. Quigg RJ, Kozono Y, Berthiaume D, Lim A, Salant DJ, Weinfeld A, et al. Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor. J Immunol 1998; 160: 4553-4560.